Share on StockTwits
 

Stock analysts at Canaccord Genuity lifted their price objective on shares of Alexion Pharmaceuticals (NASDAQ:ALXN) from $161.00 to $200.00 in a report issued on Friday, Analyst Ratings.Net reports. The firm currently has a “buy” rating on the stock. Canaccord Genuity’s target price would suggest a potential upside of 26.00% from the company’s current price.

In other Alexion Pharmaceuticals news, EVP Stephen P. Squinto sold 1,118 shares of Alexion Pharmaceuticals stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $133.31, for a total value of $149,040.58. The sale was disclosed in a filing with the SEC, which is available at this link.

Other equities research analysts have also recently issued reports about the stock. Analysts at Barclays raised their price target on shares of Alexion Pharmaceuticals from $141.00 to $181.00 in a research note to investors on Friday. They now have an “overweight” rating on the stock. Separately, analysts at Stifel Nicolaus raised their price target on shares of Alexion Pharmaceuticals from $138.00 to $207.00 in a research note to investors on Friday. They now have a “buy” rating on the stock. Finally, analysts at Brean Capital raised their price target on shares of Alexion Pharmaceuticals from $142.00 to $200.00 in a research note to investors on Thursday. They now have a “buy” rating on the stock. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have given a buy rating to the stock. Alexion Pharmaceuticals currently has an average rating of “Buy” and an average target price of $149.28.

Alexion Pharmaceuticals (NASDAQ:ALXN) traded down 2.02% during mid-day trading on Friday, hitting $158.73. 3,063,832 shares of the company’s stock traded hands. Alexion Pharmaceuticals has a 1-year low of $81.82 and a 1-year high of $169.98. The stock has a 50-day moving average of $134.5 and a 200-day moving average of $119.3. The company has a market cap of $31.123 billion and a price-to-earnings ratio of 91.63.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Thursday, January 30th. The company reported $0.87 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.83 by $0.04. The company had revenue of $441.90 million for the quarter, compared to the consensus estimate of $430.08 million. Analysts expect that Alexion Pharmaceuticals will post $3.60 EPS for the current fiscal year.

Alexion Pharmaceuticals, Inc (NASDAQ:ALXN) is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.